Gilead Sciences, Inc. v. Lee

778 F.3d 1341, 113 U.S.P.Q. 2d (BNA) 1837, 2015 U.S. App. LEXIS 2828, 2015 WL 795015
CourtCourt of Appeals for the Federal Circuit
DecidedFebruary 26, 2015
Docket2014-1159
StatusPublished
Cited by14 cases

This text of 778 F.3d 1341 (Gilead Sciences, Inc. v. Lee) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gilead Sciences, Inc. v. Lee, 778 F.3d 1341, 113 U.S.P.Q. 2d (BNA) 1837, 2015 U.S. App. LEXIS 2828, 2015 WL 795015 (Fed. Cir. 2015).

Opinion

WALLACH, Circuit Judge.

Gilead Sciences, Inc. (“Gilead”) appeals the decision of the United States District Court for the Eastern District of Virginia granting summary judgment to the Director of the United States Patent and Trademark Office (“PTO”) on whether it properly calculated the Patent Term Adjustment (“PTA”) period for U.S. Patent No. 8,148,374 (“the '374 patent”). See Gilead SCis., Inc. v. Rea, 976 F.Supp.2d 833 (2013) (“Gilead I”). Because the district court properly granted the director’s motion for summary judgment, this court affirms.

Background

I.

In 1994, Congress changed the method of how a patent term is calculated. See Pub.L. No. 103^165, § 532, 108 Stat. 4809, 4984 (1994) (amending 35 U.S.C. § 154). Under the previous statute, a patent’s term ran from the date the patent issued until the end of a period measured from that date — generally seventeen years, subject to certain extensions. See Pub.L. No. 98-417, § 201, 98 Stat. 1585, 1589-99 (1984) (adding 35 U.S.C. § 156 to provide for extensions of the term of patents covering inventions that were subject to pre- *1344 market regulatory review). Under the 1994 statutory provision, the patent term still begins on the date of issuance, but generally ends twenty years after the patent application was filed. Pub.L. No. 103-465, § 532, 108 Stat. 4809, 4984 (1994) (amending 35 U.S.C. § 154). Under the new statute, because the duration of a patent is no longer solely predicated on its date of issuance, delays in the patent examination process decrease the length of an applicant’s patent term.

In order to address this issue, in 1999, Congress enacted provisions under which patent applicants may seek PTAs for delays caused by the PTO between the filing and issuance dates of the patent application. See Pub.L. No. 106-113, § 1000(a)(9), 113 Stat. 1501, 1536 (1999). Specifically, 35 U.S.C. § 154(b), titled “Adjustment of patent term,” divides PTO actions which cause delay into three general categories. Under category A, titled “Guarantee of prompt Patent and Trademark Office responses” (“A Delay”), a patent owner may seek a PTA if, inter alia, the PTO does not issue a notification under § 132 or provide a notice of allowance under § 151 within fourteen months of an application filing. 1 35 U.S.C. § 154(b)(1)(A)®. The statute provides that “the term of the patent shall be extended 1 day for each day” the PTO does not meet its response deadlines. Id. § 154(b)(1)(A).

Category B, titled “Guarantee of no more than 3-year application pendency” (“B Delay”), allows for a one-day extension for each day the PTO fails to issue a patent three years after the actual filing date of the application, subject to certain limitations under § 154(b)(l)(B)(i)-(iii). Id. § 154(b)(1)(B). Finally, category C, titled “Guarantee of adjustments for delays due to derivation proceedings, secrecy orders, and appeals” (“C Delay”), provides PTAs for delays excluded from the B Delay. Id. § 154(b)(1)(C). The C Delay accounts for each day of delay due to an interference, secrecy order, or successful appeal.

The statute also accounts for delays attributed to applicant conduct. This appeal involves § 154(b)(2)(C), which reduces PTAs by accounting for delays caused by the patent applicant. The statutory provision provides:

(C) Reduction of period of adjustment.—
(i) The period of adjustment of the term of a patent under paragraph (1) shall be reduced by a period equal to the period of time during which the applicant failed to engage in reasonable efforts to conclude prosecution of the application.
(ii) With respect to adjustments to patent term made under the authority of paragraph (1)(B), an applicant shall be deemed to have failed to engage in reasonable efforts to conclude processing or examination of an application for the cumulative total of any periods of time in excess of 3 months that are taken to respond to a notice from the Office making any rejection, objection, argument, or other request, measuring such 3-month period from the date the notice was given or mailed to the applicant, (in) The Director shall prescribe regulations establishing the circumstances that *1345 constitute a failure of an applicant to engage in reasonable efforts to conclude processing or examination of an application.

Id. § 154 (b)(2) (C) (i) - (iii) (2011) (emphasis added).

II.

Gilead owns the '374 patent covering the compound cobicistat. The patent relates generally to “compounds and pharmaceutical compositions which ... improve [ ] the pharmacokinetics of a eo-administered drug, and methods of ... improving [ ] the pharmacokinetics of a drug by co-administration of the compounds with the drug.” '374 patent col. 111. 18-22. Gilead filed its application for the '374 patent on February 22, 2008.

When a Patent Examiner (“Examiner”) believes there is more than one patentably distinct invention recited in the claims, the Examiner issues a “restriction requirement” requesting the patent applicant to select a single invention. See 37 C.F.R. § 1.142 (2007).

On November 18, 2009, the PTO issued a restriction requirement, dividing Gilead’s claims into four groups of inventions and directing it to select a subset of its claimed inventions before further examination. Gilead responded to the restriction requirement on February 18, 2010 and selected one of the four groups of inventions for examination. While waiting for the PTO to issue a first office action on the merits, Gilead filed a supplemental information disclosure statement (“IDS”) on April 16, 2010, which disclosed two other co-pending Gilead patent applications. The PTO issued a notice of allowance on July 29, 2011 and the '374 patent issued on April 3, 2012. Gilead I, at 834-35.

Both parties agree Gilead is entitled to a PTA as a result of the PTO’s failure to meet the statutorily-mandated timeliness requirements of § 154 in issuing the '374 patent. In calculating the appropriate PTA, the PTO issued Gilead 245 days of “A Delay” for its failure to meet the mandated statutory response deadlines and 406 days of “B Delay” for its “failure to issue the patent within three years of the application’s filing date.” Id. The 651 combined days were subsequently reduced by overlapping and applicant-induced delay. The first reduction amounted to thirty-five days for overlapping delay. Id. at 834-35, see

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Califorrniaa v. Vidal
Federal Circuit, 2022
Califorrniaa v. lancu
E.D. Virginia, 2021
Atilano v. McDonough
12 F.4th 1375 (Federal Circuit, 2021)
Chudik v. Hirshfeld
987 F.3d 1033 (Federal Circuit, 2021)
Btas, Inc. v. United States
Federal Claims, 2021
SawStop Holding LLC v. Iancu
E.D. Virginia, 2020
Intra-Cellular Therapies, Inc v. Iancu
938 F.3d 1371 (Federal Circuit, 2019)
Supernus Pharmaceuticals, Inc. v. Iancu
913 F.3d 1351 (Federal Circuit, 2019)
Actelion Pharmaceuticals, Ltd. v. Matal
881 F.3d 1339 (Federal Circuit, 2018)
Hyatt v. United States Patent & Trademark Office
146 F. Supp. 3d 771 (E.D. Virginia, 2015)
Balestra v. United States
803 F.3d 1363 (Federal Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
778 F.3d 1341, 113 U.S.P.Q. 2d (BNA) 1837, 2015 U.S. App. LEXIS 2828, 2015 WL 795015, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gilead-sciences-inc-v-lee-cafc-2015.